Details

Autor(en) / Beteiligte

• Rediguieri, Camila F.
• Porta, Valentina
• G. Nunes, Diana S.
• Nunes, Taina M.
• Junginger, Hans E.
• Kopp, Sabine
• Midha, Kamal K.
• Shah, Vinod P.
• Stavchansky, Salomon
• Dressman, Jennifer B.
• Barends, Dirk M.

Titel

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metronidazole

Ist Teil von

• Journal of pharmaceutical sciences, 2011-05, Vol.100 (5), p.1618-1627

Ort / Verlag

Hoboken: Elsevier Inc

Erscheinungsjahr

2011

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing metronidazole are reviewed. Metronidazole can be assigned to Biopharmaceutics Classification System Class I. Most BE studies that were identified reported the investigated formulations to be bioequivalent, indicating the risk of bioinequivalence to be low. Formulations showing differences in bioavailability showed dissimilarities in in vitro dissolution profiles. Furthermore, metronidazole has a wide therapeutic index. It is concluded that a biowaiver for solid IR formulations is justified, provided: (a) the test product and its comparator are both rapidly dissolving; (b) meet similarity of the dissolution profiles at pH 1.2, 4.5, and 6.8; (c) the test product contains only excipients present in IR drug products approved in International Conference on Harmonisation (ICH) or associated countries in the same dosage form; and (d) if the test product contains sorbitol, sodium laurilsulfate, or propylene glycol. The test product needs to be qualitatively and quantitatively identical to its comparator with respect to these excipients. © 2011 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:1618–1627, 2011